Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…tatic lung adenocarcinoma receiving carboplatin, pemetrexed and pembrolizumab presented with subacute bilateral lower limb oedema and erythem…
… OS was not reached.Conclusions Intrathecal PD-1 inhibitor plus pemetrexed showed feasibility for LM from solid tumors with potential acti…
…rcinoma of the right lung, started treatment with cisplatin and pemetrexed. Two days after administration of chemotherapy, ischaemia of II…
…ted 76 164 life years gained. Only three accelerated approvals (nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…
…9 life years; 95% CI 7929 to 8220; 10.8%; figure 4). The use of nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…
… with treatment-naïve, stage IV NSQ NSCLC without AGAs received STK-012 subcutaneously (SC) Q3W + standard of care pembrolizumab, pemet…
…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…
…ounded 60 bags of 19 different drugs, including 5-fluorouracil, bevacizumab, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubic…
…ed favorable, with no new safety signals identified.Conclusions Ivonescimab plus chemotherapy demonstrated a clinically meaningful and stat…
…palliative ChT-IO with Atezolezumab + Pemetexed + Carboplatin + Denosumab followed by Maintenance Chemo IO with Pemetrexed + Atezolizumab…
… 32mos). We discover that after two cycles of chemotherapy with nivolumab long-term responders (PFS>12 months) have a tumor microenvironm…
…ety signals after 9 months of follow-up.All 7 patients received A2B694, were efficacy-evaluable, and had A2B694 detected post-infusion…